Results 141 to 150 of about 154,396 (266)
Factor VII Deficiency in an End-Stage Renal Disease Patient With Recurrent Thrombosis: A Case Report. [PDF]
Shakhshir A +6 more
europepmc +1 more source
ABSTRACT Objectives Focal cortical dysplasia (FCD) is the most common etiology of drug‐resistant epilepsy in children. Focal to bilateral tonic–clonic seizures (FBTCS) mark a high risk of drug‐resistant epilepsy and involve thalamocortical circuitry in their generation and propagation.
Hua Xie +8 more
wiley +1 more source
Lower Risk of Thrombosis in Blood Group O Patients: Are low clotting factor levels the reason?
Background: The ABO Blood group system has been evaluated many a times for increased risk of vascular accidents and heart diseases. This study aims to prove that the reason behind the decreased risk of thrombosis in O blood group population could be ...
Rahila Razzak +3 more
doaj
Preoperative diagnosis and laparoscopic management of Amyand's hernia with isolated factor VII deficiency: A case report. [PDF]
Bajafar A, Mohamed R, Elaagib M, Ali M.
europepmc +1 more source
Prothrombin Complex Concentrate vs Factor VII for Refractory Bleeding in Cardiac Surgery. [PDF]
Hyland SJ +6 more
europepmc +1 more source
ABSTRACT Background Ischemic stroke, a major cause of mortality and long‐term disability, results from the abrupt cessation of cerebral blood flow due to vascular occlusion or rupture. Icosapent Ethyl (EPA‐EE), approved for hypertriglyceridemia, has anti‐inflammatory and antithrombotic properties that may lessen ischemic damage.
Mitra Mahmoudi Meymand +5 more
wiley +1 more source
A Family With Factor VII Deficiency: A Possible Autosomal Dominant Transmission. [PDF]
Song Z, Garcia S, Nandhagopal T, Kim S.
europepmc +1 more source
FACTOR VII AND HEPARIN IN THROMBOSIS [PDF]
openaire +2 more sources
ABSTRACT Objective To investigate which baseline clinical and imaging characteristics best predict TSPO‐PET‐measurable reduction in glial activation following treatment of multiple sclerosis (MS), to utilize this information for designing more efficient biomarker‐based clinical trials targeting glial activation.
Marlene T. Morch +5 more
wiley +1 more source

